- 询价
- 近岸蛋白(Novoprotein)
- 中国
- DA034
- 2025年11月12日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名：
Anti-SARS-CoV-2 S-hIgG1 Neutralizing Antibody (8A5)
Anti-SARS-CoV-2 S-hIgG1 Neutralizing Antibody (8A5)
Catalog #: DA034
Spcificty: Antibody recognizes SARS-CoV-2 S Protein/ SARS-CoV-2 S-RBD Protein and block ACE-2 receptor binding
Isotype: Human IgG1
Source: Cultured in vitro under conditions free from animal derived components.
Product buffer solution: PBS, pH 7.4
Shelf life and storage: 24 months from manufacturing at <-20 °C; 1 month, 2 to 8 °C under sterile conditions.
Analyte Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
PARAMETERS TESTED ON EACH LOT
Product appearance: Liquid, may turn slightly opaque during storage
Product concentration: 2.0 mg/ml (+/- 10 %)
Immunoreactivity: 80–120 % compared to the reference sample in an ELISA test.
Purity: ≥95 %
Immunoreactivity:
|
|
000000 |
|
| Immobilized Recombinant SARS-CoV-2 S-trimer Protein (C-6His) (Cat#DRA49) at 5.0ug/ml (100uL/well) can bind Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5), the EC50 is less than 2.9ng/ml.
|
|
Immobilized Recombinant SARS-CoV-2 S Protein RBD- SD1 (C-6His) (Cat#DRA42) at 5.0ug/ml (100uL/well) can bind Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5), the EC50 is less than 4.8ng/ml. |
|
|
||
| Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5) can block Human ACE-2-Avi-His (Cat#CY51) and SARS-CoV-2 S-trimer Protein (Cat#DRA49) interaction, the IC50 for this effect is 25ng/ml. |
Bioactivity-BLI:
|
|
|
|
| Loaded SARS-CoV-2 S-trimer Protein-His(Cat#DRA49) on HIS1K Biosensor, can bind Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5)(Cat#DA034) with an affinity constant of 1.11 nM as determined in BLI assay.
|
000000 |
Loaded SARS-CoV-2 S Protein RBD-mFc V2 (Cat#DRA68) on AMC Biosensor, can bind Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5)(Cat#DA034) with an affinity constant of 31.1 nM as determined in BLI assay. |
|
|
|
|
| Loaded SARS-CoV-2 S Protein RBD V2-His(Cat#DRA72) on HIS1K Biosensor, can bind Anti-SARS-CoV-2 S-hIgG1 Neutralizing Antibody (8A5)-Fc(Cat#DA034) with an affinity constant of 0.40 nM as determined in BLI assay.
|
Loaded SARS-CoV-2 S Protein RBD-SD1-His(Cat#DRA42) on HIS1K Biosensor, can bind Anti-SARS-CoV-2 S-hIgG1 Neutralizing Antibody (8A5)-Fc(Cat#DA034) with an affinity constant of 1.23 nM as determined in BLI assay. |
|
|
|
|
|
| Loaded SARS-CoV-2 S Protein RBD-mFc V2 (Cat#DRA68) on AMC Biosensor, can bind Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5)(Cat#DA034) with an affinity constant of 0.22 nM as determined in BLI assay.
|
Loaded Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5)(Cat#DA034) on Protein A Biosensor, can bind SARS-CoV-2 S-trimer Protein-His(Cat#DRA49) with an affinity constant of 1.02 nM as determined in BLI assay. |
Bioactivity-ELISA:
|
|
|
|
| Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5)(Cat#DA034) can block Human ACE-2-Avi-His (Cat#CY51) and SARS-CoV-2 S Protein RBD-SD1-His(Cat#DRA42) interaction, the IC50 for this effect is 0.165 ug/ml. |
------ |
Anti-SARS-CoV-2 S-hIgG1 Antibody (8A5)(Cat#DA034) can block Human ACE-2-Avi-His (Cat#CY51) and SARS-CoV-2 S Protein RBD V2-His(Cat#DRA72) interaction, the IC50 for this effect is 0.115 ug/ml. |
FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验唾液或鼻咽拭子测试对于呼吸道疾病的病原体检测至关重要，未来将越来越多地用于Covid疫苗接种后的免疫检测。在这种情况下，鼻咽拭子或唾液样本的潜在高传染性通常会导致用户危险和相关的监管障碍。然而，对于唾液和鼻咽拭子检测如 SARS-CoV-2 抗原快速检测，安全设计如采用SafetyTector™ S 病毒灭活缓冲液则能很容易即可实现。 CoViD-19大流行突显了良好的诊断方法在控制公众传染病方面的重要性。除了使用核酸扩增检测 (NAT)，如现在广为人知的聚合酶链式反应 (PCR)进行早期
Purification Of Anti Peptide Antibody
antibody that could contribute to staining background. The proportion in each pool varies with the peptide immunogen. The quality of the anti-peptide serum seems to increase with multiple boosts - the first bleed may be feeble.
Neutralizing Bioassay Protocols
describe in vitro bioassays using neutralizing anti-mouse and anti-human cytokine antibodies. In general, the cytokine bioassay protocols are modified to pre-incubate the cytokine of interest with the specific neutralizing antibody prior to addition
技术资料暂无技术资料 索取技术资料
